LPTX.Leap Therapeutics, INC

Form 4: Leap Therapeutics Director Patricia Martin Acquires Stock Options

Sentiment:

SEC Form 4 Filing

📋All filings for Leap Therapeutics, INC
🔒Login to Follow

Patricia Martin, a director at Leap Therapeutics, acquired 25,000 stock options on October 2, 2024, according to a recent SEC filing.

Summary

  • Patricia Martin, a director of Leap Therapeutics, acquired 25,000 stock options on October 2, 2024.
  • The options have an exercise price of $2.45.
  • The options were granted under Leap's 2022 Equity Incentive Plan, as amended.
  • The options vest in four quarterly installments starting December 31, 2024, and continuing through September 30, 2025, contingent on continued service as a director, consultant, or service provider.
  • The options expire on October 2, 2034.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock option grants, which is neutral in sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their holdings in the company's stock.

Stakeholder Impact

  • The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards increasing the company's value.

Key Dates

DateDescription
10/02/2024Date of transaction: Patricia Martin acquired 25,000 stock options.
10/02/2024Stock option grant date.
12/31/2024First quarterly vesting date for the stock options.
03/31/2025Second quarterly vesting date for the stock options.
06/30/2025Third quarterly vesting date for the stock options.
09/30/2025Fourth quarterly vesting date for the stock options.
10/02/2034Expiration date of the stock options.
10/04/2024Date of Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.